Menu
Enrolling by invitation NCT07108179

Continuous Glucose Monitoring System: Accuracy and Prognostic Value in Critically Ill Patients

Observational Critically Ill Patients

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Continuous Glucose Monitoring (CGM) System.
Who it may be relevant to
Registry conditions: Critically Ill Patients. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Whether diabetic or non-diabetic patients, blood glucose management during ICU hospitalization is essential. This study aims to evaluate the accuracy of the iCan Continuous Glucose Monitoring (CGM) System for detecting blood glucose levels in ICU patients, as well as its value in prognostic evaluation, to provide reference for blood glucose management in critically ill patients.

Interventions

  • Device Continuous Glucose Monitoring (CGM) System
    Continuous Glucose Monitoring (CGM) System

Primary outcome measures

  • Accuracy [Time frame: Up to eight days]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years; gender not limited.
  • Expected ICU (Intensive Care Unit) stay ≥ 48 hours.
  • Patients requiring frequent blood gas monitoring in the ICU.

Exclusion criteria

  • The patient or their family refuses to use CGM for blood glucose monitoring.
  • Patients with adverse skin conditions (such as rash, active inflammation, etc.) in the device placement area, or those requiring emergency surgical intervention in that area.
  • Patients who need to undergo computed tomography (CT), X-ray, or magnetic resonance imaging (MRI) scans on the device placement area during the study period.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Continuous glucose monitoring system — Changsha

Identifiers

NCT: NCT07108179 · SN-CGM-PO-002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗